BioGeneration Ventures

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.

Escalier Biosciences B.V. is a biopharmaceutical company based in Nijmegen, the Netherlands, specializing in the development of small molecule therapeutics aimed at treating autoimmune disorders, particularly psoriasis. Founded in 2016, the company is engaged in creating innovative drug candidates that effectively target ROR?t, a critical regulator in the inflammatory process. Escalier's lead products, which are designed for both topical and oral administration, are currently in late-stage preclinical studies. These therapeutics are formulated to enhance penetration in dermal tissues, thereby maximizing target engagement at sites of inflammation while minimizing systemic drug activity and associated side effects. In addition to its operations in the Netherlands, Escalier has an office in Encinitas, California.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of innovative mucosal vaccines for infectious diseases. The company's lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infections. Mucosis utilizes its proprietary Mimopath technology, which allows for needle-free administration via the nose or mouth, effectively engaging the innate immune system through Toll-like receptor 2 (TLR2) to stimulate a robust adaptive immune response. This approach has shown promise in both animal and human proof-of-concept studies, demonstrating broad protection against various pathogens, including RSV, pneumococci, and influenza.

Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of innovative mucosal vaccines for infectious diseases. The company's lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infections. Mucosis utilizes its proprietary Mimopath technology, which allows for needle-free administration via the nose or mouth, effectively engaging the innate immune system through Toll-like receptor 2 (TLR2) to stimulate a robust adaptive immune response. This approach has shown promise in both animal and human proof-of-concept studies, demonstrating broad protection against various pathogens, including RSV, pneumococci, and influenza.

Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, focused on developing advanced antibody-drug conjugate (ADC) technology platforms for oncology. Established in 2010, the company specializes in technologies that enhance the efficacy and tolerability of ADCs. Its flagship offering, GlycoConnect, utilizes enzymatic modification of naturally occurring glycan anchor points on antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer agents. Additionally, Synaffix provides HydraSpace, a linker technology designed to improve payload solubility and reduce aggregation potential. The company's portfolio also includes a metal-free click chemistry approach applicable across pharmaceutical and academic sectors. With a strong patent portfolio, Synaffix ensures protection for its innovations through at least 2035, positioning itself as a key player in the development of proprietary ADCs from a wide range of antibodies.

Staten Biotechnology B.V. is a biotechnology company based in Nijmegen, the Netherlands, established in 2014. The company focuses on researching, developing, and producing therapeutics aimed at treating dyslipidemia, a condition characterized by abnormal lipid levels that can lead to cardiovascular disease. Staten Biotechnology specializes in the development of human monoclonal antibodies designed to neutralize apoC3, a protein that plays a crucial role in triglyceride metabolism. By targeting this protein, the company's therapeutics aim to reduce lipid accumulation in the blood and subsequently lower the risk of vascular and heart diseases.

Dezima Pharma B.V., founded in 2012 and located in Naarden, the Netherlands, specializes in the development of protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company focuses on creating innovative drug therapies, particularly a cholesteryl ester transfer protein inhibitor, which is designed to reduce low-density lipoprotein cholesterol levels. This pharmacological approach aims to lower the risk of cardiovascular diseases, thereby providing clinicians with effective treatment options for dyslipidemic patients.

Lanthio Pharma B.V. is a biopharmaceutical company based in Groningen, the Netherlands, focused on the discovery and development of novel lantipeptide drugs targeting serious medical conditions such as fibrosis, stroke, heart failure, and multiple sclerosis. Founded in 2010, the company leverages its proprietary LanthioPep technology to create peptide therapeutics that exhibit enhanced resistance to degradation, high specificity for receptors, and improved intrinsic activity. Among its key products are LP2, a selective angiotensin II type 2 receptor agonist aimed at treating fibrosis; PanCyte, designed for ischemic stroke recovery and peripheral vascular disease; and a lanthi-apelin agonist targeting the APJ receptor, which plays a role in various organ systems. Lanthio Pharma is committed to advancing therapeutic options for patients suffering from these severe diseases.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

Medisse is a Dutch company, founded in 2006, that develops, produces and markets resorbable soft tissue implants, based on bio-resorbable PTMC polymers. Medisse does yet not have commercial products but is working on the testing of its first product before market introduction. Medisse's first product will be an anti-adhesion barrier.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

FlexGen is an innovative biotech company based in Leiden, the Netherlands. FlexGen is a spin-off from Leiden University Medical Centre (LUMC) and Dutch Space (part of EADS) and has proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. FlexGen commercializes the FlexArrayer, a bench-top instrument for custom microarray and oligopool synthesis. FlexGen works at the forefront of innovative microarray and oligopool applications.

Progentix Orthobiology is a manufacturer based in Bilthoven, Netherlands, specializing in orthopedic bone graft materials. The company focuses on developing a range of osteoinductive products designed for clinical applications in bone regenerative surgery. Progentix Orthobiology aims to enhance surgical outcomes by providing innovative solutions for spine-related procedures and minimally invasive surgeries.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of innovative mucosal vaccines for infectious diseases. The company's lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infections. Mucosis utilizes its proprietary Mimopath technology, which allows for needle-free administration via the nose or mouth, effectively engaging the innate immune system through Toll-like receptor 2 (TLR2) to stimulate a robust adaptive immune response. This approach has shown promise in both animal and human proof-of-concept studies, demonstrating broad protection against various pathogens, including RSV, pneumococci, and influenza.

NovioGendix, established in 2008, is a Dutch molecular diagnostics company specializing in non-invasive liquid biopsy tests for prostate cancer. Based in Nijmegen, it offers services such as the PCA3 Test and PROGENSA PCA3 urine test for prostate cancer detection and management. The company also develops molecular diagnostic assays for various urologic cancers, collaborating with Radboud University Medical Center. Its shareholders include BioGeneration Ventures and Participatiemaatschappij Oost Nederland.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.